December 7, 2011
Bristol-Myers Squibb (BMS) and Pfizer announced that the US FDA had accepted a new drug application (NDA) for the novel anticoagulant, oral Factor Xa inhibitor Eliquis (apixaban) for the indication of prevention of stroke and systemic embolism in patients with...read more